ArticleWorld journal of hepatology2025
Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Repurposing SGLT2 Inhibitors for Cirrhotic Ascites: From Mechanistic Research to Clinical Exploration.Journal of clinical and translational hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAscites is the most common complication of cirrhosis. Current pharmacological interventions, such as diuretics, often become ineffective in advanced stages due to diuretic resistance. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated potential in enhancing urinary sodium excretion and mitigating sodium-fluid retention. This study aims to evaluate the effects of SGLT2 inhibitors on the fractional excretion of sodium (FENa) in patients with cirrhotic ascites.
aimTo determine whether adjunctive therapy with the SGLT2 inhibitor empagliflozin increases FENa compared with standard care alone in patients with cirrhosis and refractory ascites, and to evaluate its short-term safety profile.
methodsThe effect of SGLT2 inhibitor empagliflozin on FENa in patients with cirrhosis and refractory ascites is a multicenter, open-label, randomized controlled trial. A total of 70 patients with refractory ascites secondary to cirrhosis will be enrolled and randomly assigned to receive either empagliflozin 10 mg daily plus standard care or standard care alone for 14 consecutive days. The primary outcome is the change in FENa from baseline to day 14. Secondary outcomes include 24-hour urinary sodium excretion, urine volume, ascites volume (assessed by ultrasound), body weight, and safety indicators. Exploratory outcomes include changes in components of the renin-angiotensin-aldosterone system.
resultsThis article reports the study protocol only. No participant data have been collected or analyzed for this manuscript.
conclusionThis protocol evaluates whether empagliflozin, added to standard therapy, increases sodium excretion and reduces fluid overload in refractory ascites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.